Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Q4 2004 DNA CustomArray Sales Increase Ten-Fold From Year-Ago Period


While protein chips will be a new area for CombiMatrix’s array business (see story in this issue, "Jumping Off Fence, CombiMatrix Decides to Enter Developing Protein Array Marketplace"), its DNA CustomArray sales appear to be taking off. The company’s revenues for the fourth quarter of 2004 were $522,000, up from $53,000 during the same quarter a year ago. Revenues comprised $390,000 from government contracts — $73,000 of which were array sales — and $132,000 from CustomArray products and services.

Notably, revenues from CustomArray products almost doubled compared to the third quarter. This trend of sequential growth seems to continue: As of last week, CombiMatrix already had microarray orders that nearly equaled all of its array sales in the fourth quarter.

However, CEO Amit Kumar remained cautious about whether chip sales will be able to keep their momentum. “Because it is difficult to estimate sales growth for such a new product, we do not provide financial guidance at this time but may do so in the future,” he said.

Regarding the launch of the MatrixArray, which CombiMatrix developed for Roche, Kumar said that no decision has been made yet.

He also mentioned that a number of higher density DNA arrays are in the works and that a 95K array is scheduled to be launched sometime next year. In addition, the company is working on new chip formats. “As we go forward, there are a number of other different formats, which are addressing some specific market niches such as the diagnostics market,” he said.

The company spent $1.4 million on research and development during the quarter, down from $1.9 million during the same period a year earlier.

CombiMatrix’s net loss for the quarter was $4.2 million, up from $4.1 million during the same quarter in 2003.

As of Dec. 31, 2004, CombiMatrix had $23.7 million in cash, cash equivalents and short-term investments.

— JK

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.